Correlation Between Enorama Pharma and Dow Jones
Can any of the company-specific risk be diversified away by investing in both Enorama Pharma and Dow Jones at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enorama Pharma and Dow Jones into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enorama Pharma AB and Dow Jones Industrial, you can compare the effects of market volatilities on Enorama Pharma and Dow Jones and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enorama Pharma with a short position of Dow Jones. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enorama Pharma and Dow Jones.
Diversification Opportunities for Enorama Pharma and Dow Jones
-0.57 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Enorama and Dow is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Enorama Pharma AB and Dow Jones Industrial in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dow Jones Industrial and Enorama Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enorama Pharma AB are associated (or correlated) with Dow Jones. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dow Jones Industrial has no effect on the direction of Enorama Pharma i.e., Enorama Pharma and Dow Jones go up and down completely randomly.
Pair Corralation between Enorama Pharma and Dow Jones
Assuming the 90 days trading horizon Enorama Pharma AB is expected to generate 11.39 times more return on investment than Dow Jones. However, Enorama Pharma is 11.39 times more volatile than Dow Jones Industrial. It trades about 0.04 of its potential returns per unit of risk. Dow Jones Industrial is currently generating about 0.08 per unit of risk. If you would invest 419.00 in Enorama Pharma AB on August 29, 2024 and sell it today you would lose (58.00) from holding Enorama Pharma AB or give up 13.84% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 99.6% |
| Values | Daily Returns |
Enorama Pharma AB vs. Dow Jones Industrial
Performance |
| Timeline |
Enorama Pharma and Dow Jones Volatility Contrast
Predicted Return Density |
| Returns |
Enorama Pharma AB
Pair trading matchups for Enorama Pharma
Dow Jones Industrial
Pair trading matchups for Dow Jones
Pair Trading with Enorama Pharma and Dow Jones
The main advantage of trading using opposite Enorama Pharma and Dow Jones positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enorama Pharma position performs unexpectedly, Dow Jones can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dow Jones will offset losses from the drop in Dow Jones' long position.| Enorama Pharma vs. Cantargia AB | Enorama Pharma vs. Enzymatica publ AB | Enorama Pharma vs. Lidds AB | Enorama Pharma vs. BioArctic AB |
| Dow Jones vs. Kaltura | Dow Jones vs. Artisan Partners Asset | Dow Jones vs. US Global Investors | Dow Jones vs. Analog Devices |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |